<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704348</url>
  </required_header>
  <id_info>
    <org_study_id>421917</org_study_id>
    <nct_id>NCT05704348</nct_id>
  </id_info>
  <brief_title>Sleeve-pex: A Randomized Trial to Reduce Reflux After Sleeve Gastrectomy</brief_title>
  <official_title>A Clinical Intervention Study Exploring Gastropexy as a Measure to Reduce Gastro-oesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Forde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Forde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to test gastropexy as a measure to reduce reflux in&#xD;
      morbidly obese patients being submitted to sleeve gastrectomy. The main questions it aims to&#xD;
      answer are:&#xD;
&#xD;
      Does gastropexy reduce reflux symptoms? Does gastropexy reduce objective evidence of reflux?&#xD;
      Participants will be randomized to gastropexy or no gastropexy, and researchers will compare&#xD;
      these groups to see if reflux (symptoms / objective evidence of) is different in the two&#xD;
      groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laparoscopic sleeve gastrectomy (LSG) has become the most commonly performed bariatric&#xD;
      procedure worldwide. LSG consists of a longitudinal resection of the stomach leaving the&#xD;
      intestines intact, thereby lowering the risk for side-effects due to rerouting of the small&#xD;
      bowel. However, gastro-esopageal reflux disease (GERD) has been reported to increase after&#xD;
      LSG. Our hypothesis is that GERD is mainly due to intrathoracic migration of the gastric&#xD;
      remnant. The aim of this study is to explore if suturing the gastric remnant to the&#xD;
      gastrocolic ligament (gastropexy) will prevent intrathoracic migration and thereby reduce the&#xD;
      development of reflux.&#xD;
&#xD;
      Patients planned for a sleeve gastrectomy will be invited to participate, and participating&#xD;
      patients will be randomized to pexi or no pexi. According to power calculations a total of&#xD;
      550 patients will be randomized in the study. Follow-up will be at six weeks, one-, two- and&#xD;
      five years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The patient and the healtcare workers will be masked as to whether a pexi has been performed or not.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants using acid-reducing medication (ARM) or having had reoperations due to GERD</measure>
    <time_frame>Two years</time_frame>
    <description>ARM: Daily use of ARM for the last month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic findings</measure>
    <time_frame>Two years</time_frame>
    <description>Visible oesophagitis according to the LA classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient related outcome</measure>
    <time_frame>Two years</time_frame>
    <description>GerdQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH-metry</measure>
    <time_frame>Two years</time_frame>
    <description>pH measurement by Bravo capsule</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>No gastropexy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sleeve gastrectomy without gastropexy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastropexy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sleeve gastrectomy with gastropexy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve gastrectomy with gastropexy</intervention_name>
    <description>Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.</description>
    <arm_group_label>Gastropexy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve gastrectomy without gastropexy</intervention_name>
    <description>Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.</description>
    <arm_group_label>No gastropexy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planned for bariatric surgery with primary LSG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18 yrs&#xD;
&#xD;
          -  Use of ARM for other reasons than reflux&#xD;
&#xD;
          -  Previous antireflux surgery&#xD;
&#xD;
          -  Inability to comprehend and respon to patient related outcome (PRO) questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Villy Vage, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helse Forde</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Villy Vage, MD PhD</last_name>
    <phone>47 90863744</phone>
    <email>villy.vage@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Andersen, PhD</last_name>
    <phone>47 48278186</phone>
    <email>john.roger.andersen@helse-forde.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helse Forde</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Villy Våge, PhD</last_name>
      <phone>47 90863744</phone>
      <email>villy.vage@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>John Roger Andersen, PhD</last_name>
      <phone>47 48278186</phone>
      <email>john.roger.andersen@helse-forde.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helse Forde</investigator_affiliation>
    <investigator_full_name>Villy Våge</investigator_full_name>
    <investigator_title>Project leader</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information about Sleeve-pex will be found at the SOReg-N webpage.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The study protocol including analysis plan and formula for informed consent will be available at the SOReg-N webpage from the beginning of the study.</ipd_time_frame>
    <ipd_access_criteria>The study protocol is available at SOReg-N webpage. Data from the study will be made available for other researchers on request if approved by the ethical review board.</ipd_access_criteria>
    <ipd_url>https://helse-bergen.no/avdelinger/laboratorieklinikken/medisinsk-biokjemi-og-farmakologi/norsk-kvalitetsregister-for-fedmekirurgi-soreg-norge</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

